LATERAL PHARMA PTY LTD Information

Lateral Pharma Pty Ltd Is a privately-owned Melbourne AU-based biotechnology company that commenced operations in May 2015 to repurpose LAT8881, a Phase 2 ready orally-available compound with extensive toxicology and human safety data, into new high potential pain and respiratory indications. Lateral aims to demonstrate efficacy in a human clinical Phase 2 proof-of-concept study using LAT8881 to treat neuropathic pain within the next 12 months. Lateral Pharma has discovered a new class of naturally-derived peptide motifs and their novel target family of proteins that restore normal tissue function in mammals under conditions of damage and cellular stress. Small synthetic peptides derived from growth hormone and at least three other proteins are active in animal models of neuropathic pain, osteoarthritis, obesity, COPD, severe influenza A and recently in initial data in SARS-CoV-2. Lateral has filed multiple patents protecting its intellectual property Lateral is focussed on developing its drugs for the treatment of Neuropathic pain but subject to additional funding will also explore development in respiratory diseases such as Influenza, SARS-CoV-2, COPD, Steroid resistant asthma, and Post-COVID Syndrome (Long-COVID).